Work

1696P A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1789

Authors: S. George, U.N. Vaishampayan, A. Hutson, A. Groman, C.L. Roche, L. Herbst, R. Kallicharsn-Smith, A-M. DiRaddo, E. Farrell, D. Kilari, D. Gopalakrishnan, E. Heath, E. Wulff-Burchfield, L.J. Appleman, R. Parikh

Institutions: Roswell Park Comprehensive Cancer Center, University of Michigan, Michigan Medicine, Froedtert Hospital, Medical College of Wisconsin, The Barbara Ann Karmanos Cancer Institute, University of Kansas Medical Center, UPMC Hillman Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4402704849

FWCI:

Cites:

Cited by:

Related to: 10